NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan



    BEDMINSTER, N.J., Oct. 25 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:  
NPSP) announced today the approval of cinacalcet hydrochloride by the Japanese
Pharmaceuticals and Medical Devices Agency for the treatment of secondary
hyperparathyroidism.  As a result, NPS will receive a milestone payment plus
royalties from Kirin Pharma, a wholly owned subsidiary of Kirin Holdings,
which will market the drug in Japan.  Kirin licensed cinacalcet from NPS in
1995 for development and commercial sale in Japan, China, North and South
Korea, and Taiwan.
    Cinacalcet is an oral medication for the treatment of secondary
hyperparathyroidism in patients with chronic kidney disease on dialysis.  It
regulates the over-secretion of parathyroid hormone (PTH) in patients with
chronic kidney insufficiency by acting directly on the parathyroid gland
calcium-sensing receptor.  Elevated levels of PTH, the hallmark of secondary
hyperparathyroidism, are associated with altered metabolism of calcium and
phosphorus, bone pain, fractures, and an increased risk for cardiovascular
death.  The drug is currently marketed in the United States and Europe by
Amgen as a treatment for this condition and for the treatment of elevated
levels of calcium in patients with parathyroid carcinoma.
    NPS president and CEO Dr. Tony Coles stated:  "We congratulate our
partner Kirin Pharma for obtaining approval to market cinacalcet in Japan as a
treatment for secondary hyperparathyroidism.  This first-in-class compound
treats a serious complication of chronic kidney disease for which patients in
Japan with this condition have had no therapeutic alternative."
    Kirin Pharma general manager of strategic product planning, T. Oishi,
stated:  "Approximately 30 to 40 % of dialysis patients in Japan have
secondary hyperparathyroidism. The results of our clinical studies have
demonstrated significant benefits of daily administration of cinacalcet in
individuals with this serious condition. We look forward to bringing this drug
to patients in Japan."
    
    About NPS
    
    NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The company has drug candidates in various
stages of clinical development. Additional information is available on the
company's website, http://www.npsp.com.
    Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. All information in this press release is as of October 25, 2007
and we undertake no duty to update this information. A more complete
description of these risks can be found in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the
year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the
quarter-ended June 30, 2007.




For further information:

For further information: Brandi Simpson of NPS Pharmaceuticals, Inc., 
+1-908-450-5616 Web Site: http://www.npsp.com

Organization Profile

NPS PHARMACEUTICALS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890